16 November 2026
Novo's full Wegovy trial data in kids aged 6 to 11 show a sharp drop in BMI
Novo Nordisk released full results from a late-stage trial in which children aged 6 to under 12 on Wegovy saw their BMI fall 17.4% over 68 weeks, while kids on a placebo saw theirs rise.
Novo Nordisk has published the full numbers from a late-stage study of its weight-loss injection Wegovy in children aged 6 to under 12. The drug is already approved for obesity in kids 12 and older, but no medicine is approved for younger children. The new results offer evidence that Wegovy could potentially fill that gap.
What happened
The trial followed 167 children for 68 weeks. Every child, whether on the drug or on a placebo (a dummy injection), also got a lower-calorie diet and more exercise. Most were seriously affected at the start: 85% had moderate or severe obesity, and close to half already had a related problem such as high blood pressure, high cholesterol or sleep apnea.
Body mass index, or BMI, is a measure of weight relative to height. Among children who stayed on treatment, BMI fell 17.4% on Wegovy and rose 2.2% on placebo, a gap of about 19.7 percentage points. Counting every child, including those who stopped treatment, the gap was about 16.2 points. More than 40% of children on Wegovy who stayed on treatment were no longer classed as having obesity by the end, a headline figure Novo first shared in September.
Novo said the drug's overall safety and tolerability in children were consistent with what was seen in adult trials, and that it saw no safety concerns related to growth or puberty. Its obesity medical lead, Dr. Andrea Traina, also said the study cannot show whether treating obesity young changes how the disease plays out over a lifetime, calling that "still an evidence gap."
Why it matters
The potential market is large. The World Obesity Federation estimates about 177 million children and teens aged 5 to 19 had obesity in 2025, a number it projects will reach 228 million by 2040. If regulators ever approved it for younger children, that would widen the pool of patients for a drug class that has become one of the most closely watched businesses in health care.
For Novo shareholders, the backdrop matters too. Noorult data shows the company's US-listed shares closed at $40.66 on November 13, down about 13% over the past year. Positive trial data does not by itself guarantee approval or sales, and the company itself says long-term questions remain open.
What to watch
- Whether Novo seeks approval from regulators to use Wegovy in children under 12, and how they respond.
- Follow-up research on what happens as treated children grow up, including whether they need to stay on the drug.
- Any further detail on safety as more of the trial data is examined.
The companies in this story
Based on reporting by CNBC: Novo says Wegovy injection lowers BMI and obesity rates in children in trial. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion